期刊
INVESTIGATIONAL NEW DRUGS
卷 39, 期 2, 页码 458-468出版社
SPRINGER
DOI: 10.1007/s10637-020-01003-3
关键词
Lung adenocarcinoma; Acquired radioresistance; Chemotherapeutic drugs; SN-38; BCRP
资金
- Zhejiang Provincial Natural Science Foundation of China [LQ19H310001]
- Zhejiang Provincial Medicine and Health Science Foundation [2020RC027]
- National Natural Scientific Foundation of China [81803631, 81773242]
The study compared the sensitivity changes of lung adenocarcinoma cells to conventional chemotherapeutic drugs under radioresistant circumstances and found increased toxicities for paclitaxel, docetaxel, and SN-38 in radioresistant cells. The downregulation of the efflux transporter BCRP by long-term fractionated irradiation was identified as a key factor contributing to the increased cytotoxicity of SN-38. These results suggest that irinotecan (the prodrug of SN-38) could be a promising drug candidate for lung adenocarcinoma patients with acquired radioresistance.
Chemotherapy is usually the subsequent treatment for non-small cell lung cancer patients with acquired radioresistance after long-term fractionated radiotherapy. However, few studies have focused on the selection of chemotherapeutic drugs to treat lung adenocarcinoma patients with radioresistance. Our study compared the sensitivity changes of lung adenocarcinoma cells to conventional chemotherapeutic drugs under radioresistant circumstances by using three lung adenocarcinoma cell models, which were irradiated with fractionated X-rays at a total dose of 60 Gy. The results showed that the toxicities of paclitaxel, docetaxel and SN-38 were increased in radioresistant cells. The IC50 values of docetaxel and SN-38 decreased 0 similar to 3 times and 3 similar to 36 times in radioresistant cells, respectively. Notably, the A549 radioresistant cells were approximately 36 times more sensitive to SN-38 than the parental cells. Further results revealed that the downregulation of the efflux transporter BCRP by long-term fractionated irradiation was an important factor contributing to the increased cytotoxicity of SN-38. In addition, the reported miRNAs and transcriptional factors that regulate BCRP did not participate in the downregulation. In conclusion, these results presented important data on the sensitivity changes of lung adenocarcinoma cells to chemotherapeutic drugs after acquiring radioresistance and suggested that irinotecan (the prodrug of SN-38) might be a promising drug candidate for lung adenocarcinoma patients with acquired radioresistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据